Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Non-Current Assets (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Non-Current Assets for 15 consecutive years, with $388.8 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Assets fell 4.68% year-over-year to $388.8 million; the TTM value through Mar 2026 reached $1.4 billion, up 10.68%, while the annual FY2025 figure was $351.2 million, 4.81% down from the prior year.
  • Non-Current Assets hit $388.8 million in Q1 2026 for Corcept Therapeutics, up from $351.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $408.0 million in Q1 2025 and bottomed at $77.3 million in Q2 2022.
  • Average Non-Current Assets over 5 years is $212.1 million, with a median of $162.5 million recorded in 2023.
  • Year-over-year, Non-Current Assets crashed 55.94% in 2022 and then skyrocketed 167.39% in 2025.
  • Corcept Therapeutics' Non-Current Assets stood at $84.2 million in 2022, then skyrocketed by 93.5% to $162.9 million in 2023, then surged by 126.52% to $369.0 million in 2024, then dropped by 4.81% to $351.2 million in 2025, then increased by 10.72% to $388.8 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $388.8 million, $351.2 million, and $282.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.